CHPA Applauds Historic FDA Approval of First-Ever OTC Daily Oral Contraceptive

Share page:

(WASHINGTON, D.C.) — Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville today released the below statement following the U.S. Food and Drug Administration (FDA) approving Opill®, a once-daily oral contraceptive, as the first nationwide prescription-strength oral contraceptive for use over-the-counter (OTC):

“Today’s historic action by the FDA is a major step forward in helping American women meet their reproductive health needs. More than 40 million U.S. women are at risk of experiencing an unexpected pregnancy each year, and this landmark approval removes barriers and increases access to a safe and effective contraceptive option. This Rx-OTC switch, and other first-in-class switches, provide groundbreaking public health benefits by empowering consumers to take greater control over their own health.”

The Consumer Healthcare Products Association (CHPA), founded in 1881, is the national trade association representing the leading manufacturers and marketers of consumer healthcare products, including over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. CHPA is committed to empowering self-care by ensuring that Americans have access to products they can count on to be reliable, affordable, and convenient, while also delivering new and better ways to get and stay healthy. Visit